RenovoRx Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RenovoRx Inc. - overview
Established
2012
Location
Los Altos, CA, US
Primary Industry
Medical Devices & Equipment
About
Founded in 2009 by Kamran Najmabadi and Ramtin Agah, and based in California, US, RenovoRx is a clinical-stage biopharmaceutical company focused on developing targeted combination therapies for difficult-to-access cancers. In April 2018, RenovoRx Inc. raised USD 8. 31 million led by Boston Scientific Ventures, with participation from btov Partners.
The company trades on the NASDAQ under the ticker symbol, RNXT. The firm employs its proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform that delivers precise therapeutic doses directly to tumors, minimizing systemic toxicities. Their lead product, RenovoGem™, combines the chemotherapeutic gemcitabine with TAMP and is used for treating locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy. RenovoGem is used for treating both pancreatic and bile duct cancers.
Current Investors
The Angels' Forum, The Halo Fund Management Company, Golden Seeds
Primary Industry
Medical Devices & Equipment
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.renovorx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.